Evidence map›Paper›PMID 37880619›Full record

ArticleBMC health services research2023

Impact of HIV treat-all and complementary policies on ART linkage in 13 PEPFAR-supported African countries.

Anna Russell, Andre R Verani, Sherri Pals, Valamar M Reagon, Lorraine N Alexander, Eboni T Galloway, Mayer Magdalene Mange, Pearl Kalimugogo, Ponesai Nyika, Yasmine Moussa Fadil and 12 more

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Programme Science in PEPFAR: a pathway to a sustainable HIV response.Journal of the International AIDS Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 7 countries.

Anna RussellIndependent Researcher (formerly Centers for Disease Control & Prevention), 1600 Clifton Rd, GA, 30333, Atlanta, USA. arussell.8515@gmail.com.
Andre R VeraniDivision of Global HIV & TB, Centers for Disease Control & Prevention (CDC), Atlanta, USA.
Sherri PalsDivision of Global HIV & TB, Centers for Disease Control & Prevention (CDC), Atlanta, USA.
Valamar M ReagonDivision of Global HIV & TB, Centers for Disease Control & Prevention (CDC), Atlanta, USA.
Lorraine N AlexanderDivision of Global HIV & TB, Centers for Disease Control & Prevention (CDC), Atlanta, USA.
Eboni T GallowayDivision of Global HIV & TB, Centers for Disease Control & Prevention (CDC), Atlanta, USA.
Mayer Magdalene MangeDivision of Global HIV and TB, Center for Global Health, CDC, Yaoundé, Cameroon.
Pearl KalimugogoDivision of Global HIV and TB, Center for Global Health, CDC, Windhoek, Namibia.
Ponesai NyikaDivision of Global HIV and TB, Center for Global Health, CDC, Harare, Zimbabwe.
Yasmine Moussa FadilDivision of Global HIV and TB, Center for Global Health, CDC, Yaoundé, Cameroon.
Appolonia AokoDivision of Global HIV and TB, Center for Global Health, CDC, Nairobi, Kenya.
Fred Mugyenyi AsiimweDivision of Global HIV and TB, Center for Global Health, CDC, Maseru, Lesotho.
Akudo IkpeazuSexually Transmitted Infections Control and Hepatitis Program (NASCP), National AIDS, Federal Ministry of Health, Abuja, Nigeria.
Dumbani KayiraDivision of Global HIV and TB, Center for Global Health, CDC, Lilongwe, Malawi.
Mpho LetebeleDivision of Global HIV and TB, Center for Global Health, CDC, Gaborone, Botswana.
Alice MaidaDivision of Global HIV and TB, Center for Global Health, CDC, Lilongwe, Malawi.
Daniel MagesaDivision of Global HIV and TB, Center for Global Health, CDC, Dar es Salaam, Tanzania.
Gram MutandiDivision of Global HIV and TB, Center for Global Health, CDC, Windhoek, Namibia.
Annie C MwilaDivision of Global HIV and TB, Center for Global Health, CDC, Lusaka, Zambia.
Dennis OnotuDivision of Global HIV and TB, Center for Global Health, CDC, 1600 Clifton Rd, GA, 30333, Atlanta, Nigeria.
Kingsly Tse NkwohDivision of Global HIV and TB, Center for Global Health, CDC, Yaoundé, Cameroon.
Evelyn WangariDivision of Global HIV and TB, Center for Global Health, CDC, Nairobi, Kenya.
Centers for Disease Control and Prevention · USGlobal Health Systems Solutions · CMCenters for Disease Control and Prevention · KEWorld Health Organization - Malawi · MWCenter for Global Health · USFederal Ministry of Health · NGLesotho Planned Parenthood Association · LSManagement and Development for Health · TZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2015, the World Health Organization recommended that all people living with HIV begin antiretroviral treatment (ART) regardless of immune status, a policy known as 'Treat-All to end AIDS', commonly referred to as Treat-All. Almost all low- and middle-income countries adopted this policy by 2019. This study describes how linkage to treatment of newly diagnosed persons changed between 2015 and 2018 and how complementary policies may have similarly increased linkage for 13 African countries. These countries adopted and implemented Treat-All policies between 2015 and 2018 and were supported by the U.S. Government's President's Emergency Plan for AIDS Relief (PEPFAR). The focuses of this research were to understand 1) linkage rates to ART initiation before and after the adoption of Treat-All in each country; 2) how Treat-All implementation differed across these countries; and 3) whether complementary policies (including same-day treatment initiation, task-shifting, reduced ART visits, and reduced ART pickups) implemented around the same time may have increased ART linkage.

methodsHIV testing and treatment data were collected by PEPFAR country programs in 13 African countries from 2015 to 2018. These countries were chosen based on the completeness of policy data and availability of program data during the study period. Program data were used to calculate proxy linkage rates. These rates were compared relative to the Treat All adoption period and the adoption of complementary policies.

resultsThe 13 countries experienced an average increase in ART linkage of 29.3% over the entire study period. In examining individual countries, all but two showed increases in linkage to treatment immediately after Treat All adoption. Across all countries, those that had adopted four or more complementary policies showed an average increased linkage of 39.8% compared to 13.9% in countries with fewer than four complementary policies.

conclusionsEleven of 13 country programs examined in this study demonstrated an increase in ART linkage after Treat-All policy adoption. Increases in linkage were associated with complementary policies. When exploring new public health policies, policymakers may consider which complementary policies might also help achieve the desired outcome of the public health policy.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsAfricaAnti-Retroviral AgentsHumansPublic PolicyAnti-Retroviral AgentsHIV/AIDSLinkageRetentionTest and startTreat-all

Identifiers

PMID37880619
PMCPMC10598983
OpenAlexW4387950089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.